Skip to content

Advertisement

  • Poster presentation
  • Open Access

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report

  • 1,
  • 1,
  • 1,
  • 1 and
  • 1Email author
Pediatric Rheumatology20119 (Suppl 1) :P9

https://doi.org/10.1186/1546-0096-9-S1-P9

  • Published:

Keywords

  • Rhinitis
  • Gastroenteritis
  • Anakinra
  • Residual Symptom
  • Respiratory Viral Infection

Background

V198M mutation has been identified in more than one CAPS phenotype and is difficult to treat.

Aim

To report effects of prolonged selective IL-1β inhibition with canakinumab in a CAPS phenotype related to V198M mutation.

Methods

A 9-year old boy, diagnosed with symptomatic MWS and evidence of a V198M mutation (father also V198M), only partially responsive to anakinra, participated in a phase III study of canakinumab in CAPS patients (N=166). Study treatment was 8-weekly administration of canakinumab by s.c. injection, 150 mg to adults and 2 mg/kg to patients ≤40 kg for up to 2 years. Administration frequency and dose (maximum 600 mg or 8 mg/kg [≤40 kg]) were increased in case of residual symptoms.

Results

After insufficient response to per-protocol canakinumab dose, the patient received high dose canakinumab (10 mg/kg, i.v.) every 4 weeks from Day 20 onwards to >440 days. Disease activity improved from severe to moderate at Day 48 and remained stable including normal CRP and SAA values (<10 mg/L). Temporary mild adverse events (AE) were not suspected to be treatment-related (upper respiratory viral infection, gastroenteritis, and rhinitis). Night sweats, dry lips and skin persisted until last assessments. No serious AEs /infections were reported in this patient.

Conclusion

Based on our experience in this patient and a review of literature on efficacy of IL-1 inhibition in CAPS patients with V198M mutation, high dose canakinumab i.v* with increased dosing frequency yields symptomatic relief without evidence of increased AE. Confirmation of our observation in more patients with similar genetic and clinical presentation is needed.

*The posology used for this case is not in line with the approved posology of canakinumab

Authors’ Affiliations

(1)
Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tübingen, Germany

Copyright

Advertisement